Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 06 - 23 save search
Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
RCUS 4 | $14.94 1.77% 72K
|
Health Technology
|
| O: -0.53%
H: 5.66%
C: 3.4%
phase 2 lung cancer cancer arcus
AGTC to Host Conference Call to Discuss Achromatopsia 12-Month Data in its Ongoing Phase 1/2 Clinical Trials
Published: 2021-06-23 (Crawled : 21:00) - agtc.com
OTIC | $0.077
|
Health Technology
|
| O: -0.89%
H: 3.14%
C: 1.35%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 5.28%
H: 4.56%
C: -1.59%
ongoing clinical trials phase 1 trial conference phase 2 phase 3
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.81%
H: 2.24%
C: 1.02%
treatment solid tumors ongoing phase 1 trial phase 2 keytruda
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)
Published: 2021-06-23 (Crawled : 16:00) - biospace.com/
DRRX | $0.8247 2.45% 13K
|
Health Technology
|
| O: 0.59%
H: 1.18%
C: -1.18%
phase 1 nash liver trial conference phase 2 phase 1b hepatitis phase 2b
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Published: 2021-06-23 (Crawled : 16:00) - biospace.com/
ATHE | $2.13 10K
|
Health Technology
|
| O: 7.69%
H: 0.71%
C: -6.43%
phase 2 europe trial ath434
JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
Published: 2021-06-23 (Crawled : 14:15) - janone.com
JAN | $4.9 13.16% 290K
|
Industrial Services
|
| O: -2.04%
H: 11.84%
C: -3.51%
phase 2 distribution phase 2b trial
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: 2.68%
H: 0.0%
C: -9.4%
phase 1 trial submission phase 2 phase 3 application
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $2.03 -0.98% 36K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | News | $273.38 0.54% 790K
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
Published: 2021-06-23 (Crawled : 07:00) - prnewswire.com
BHVN | News 0 d | $39.92 4.15% 1.3M
|
Health Technology
|
| O: 0.29%
H: 1.88%
C: 0.25%
phase 1 collaboration trial phase 2 phase 3
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Published: 2021-06-23 (Crawled : 07:00) - globenewswire.com
TLSA | News | $0.761 0.98% 2.2M
|
Health Technology
|
| O: 7.83%
H: 3.63%
C: -2.82%
covid phase 2 foralumab collaboration antibody trial
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.